ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 3 | Page 16

«ΨΥΧΟΛΟΓΙΑ έρευνα & εφαρμογές» Τόμος 1, Τεύχος 3, 2018 ISSN: 2623-3673
60. A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide
Treatment in Psychiatric Patients With Mood and Anxiety Disorders. Brennan F,
Gardner K, Lombard J, Perlis R, Fava M, Harris H, Scott R. Prim Care Companion
CNS Disord. 2015 Apr 16;17(2).
61. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major
Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness
Studies. Rosenblat J, Lee Y, McIntyre R. J Clin Psychiatry. 2017 Jun;78(6):720-729.
62. Overstatements in abstract conclusions claiming effectiveness of interventions in
psychiatry: A meta-epidemiological investigation. Kiyomi Shinohara , Aya M.
Suganuma, Hissei Imai, Nozomi Takeshima, Yu Hayasaka, Toshi A. Furukawa.
Journals.PLOS https://doi.org/10.1371/journal.pone.0184786
63. The Promise and Reality of Pharmacogenetics in Psychiatry Peter P. Zandi and
Jennifer T. Judy. Psychiatr Clin North Am. 2010 Mar; 33(1): 181–224.
64. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic
epidermal necrolysis: US FDA recommendations. Ferrell PB Jr, McLeod HL.
Pharmacogenomics. 2008 Oct;9(10):1543-6.
65. How is genetic testing evaluated? A systematic review of the literature Erica
Pitini, Corrado De Vito, Carolina Marzuillo, Elvira D’Andrea, Annalisa Rosso,
Antonio Federici, Emilio Di Maria & Paolo Villari
European Journal of Human
Geneticsvolume 26, pages605–615 , February 2018.
66. Direct-to-Consumer Genetic Testing: A Comprehensive View .Pascal Su. Yale J
Biol Med. 2013 Sep; 86(3): 359–365.
SUMMARY
Existing medicines used to treat mental illnesses, including antipsychotics,
antidepressants and mood stabilizers, are only effective in a subset of patients or
cause some responses and are often associated with side effects that undermine
compliance. In recent years, research interest has been increased in the use of
pharmacogenetics and pharmacogenomics to personalize the use of these
therapies in order to maximize their efficacy and tolerance. Along with this clinical
dimension with the help of pharmacogenetics, the mechanisms of action of
psychotropic drugs as well as the biological explanation of psychiatric morbidity are
also investigated. However, there seems to be a long way to go in this direction.
This article examines the progress made in the research to understand how genetic
factors affect the efficacy of psychotropic drugs and the challenges posed by
transferring research findings to clinical practices that benefit patients with mental
disorders.